SOURCE: EmpowHER

EmpowHER

June 17, 2010 06:00 ET

REMINDER: Interview Advisory: Leading Women's Health Advocate to Testify to FDA Panel About Breakthrough Medication for Women's Sexual Disorders

Michelle King Robson of EmpowHER to Provide Personal Story of Need for New Treatments for Women

SCOTTSDALE, AZ--(Marketwire - June 17, 2010) -


WHAT:      Michelle King Robson http://www.empowher.com/michelle, one of the
           nation's leading women's health and wellness advocates and       
           Founder, Chairperson and CEO of EmpowHER, a health media company 
           for women, will share her personal testimony with a panel of the 
           Food and Drug Administration on June 18, 2010 about women's      
           sexual health, and a condition called Hyposexual Desire Disorder 
           (HSDD), also known as low libido.                                
                                                                            
           "I am speaking about my personal story following my hysterectomy 
           and its adverse affects on my own sexual health. And, I'm        
           bringing with me the voice of millions of women who come to      
           EmpowHER.com every year to talk about their own health and       
           wellness. Many of these women share their personal health        
           struggles with each other, and with caregivers and medical       
           experts on the site because they feel like they are 'not the     
           same' person they once were," King Robson said.                  
                                                                            
           The FDA panel is expected to make a final decision about the     
           approval of a medication called Flibanserin -- the so-called     
           "pink pill or female Viagra." King Robson cites the fact that    
           Viagra has been around for more than a decade and women's sexual 
           enhancement medications have languished in the approval process  
           for years. "It's time for women's sexual disorders to be         
           addressed by the medical community. This medication could pave   
           the way for many new therapies," she said, noting that EmpowHER  
           has set up a special resource section for women and the media,   
           specifically dedicated to this issue, which can be found at      
           www.empowher.com/pinkpill.                                       
                                                                            
           King Robson and EmpowHER have not been personally or commercially
           involved with Flibanserin or its manufacturer, drug maker        
           Boehringer Ingelheim. Nonetheless, King Robson maintains, "This  
           is a step in the right direction. Flibanserin won't be the silver
           bullet for all women, but that is not the point. The point is    
           that women's sexual health is, by virtue of this FDA hearing and 
           the preponderance of this drug, being given its due. Whatever    
           other drugs, treatments or procedures follow Flibanserin into the
           market will only further advance and improve women's sexual      
           health. I have long maintained, if men had hysterectomies, or    
           experienced menopause or hormonal issues; this problem would have
           been solved decades ago. It's time for women to be heard. And,   
           I'm honored to have an opportunity to be a mouthpiece for tens of
           millions of women who suffer in silence with this dysfunction."  
                                                                            
WHEN:      King Robson will testify to the FDA panel in Washington, D.C. on 
           June 18, 2010.                                                   
                                                                            
WHO:       Michelle King Robson is one of the nation's leading women's      
           health advocates. In 2006, Michelle's advocacy work pushed her to
           lead a petition and mail-in campaign against a major             
           pharmaceutical company whom she believes was pushing a "one-size-
           fits-all" drug and trying to halt the production of compounded   
           medicine to treat hormonal issues -- this was later recorded by  
           the FDA as the second largest campaign of its kind in history.   
           Her efforts have helped pave the way for increased awareness and 
           action regarding a number of women's health disorders, including 
           menopause, sexual dysfunction, breast cancer and many others.    
           Following her own personal medical nightmare after undergoing an 
           unnecessary hysterectomy, King Robson began advocating for other 
           women and eventually founded a health media company for women    
           whose website, www.EmpowHER.com, was launched 18 months ago.     
           Today, EmpowHER is the 5th largest website in its category,      
           reaching almost a million women per month.                       
                                                                            
WHY:       King Robson's testimony is a formal part of the final approval   
           process for medications presented to the FDA. Besides leading    
           physicians and scientists who have studied the medication, the   
           panel seeks voices from those whose lives have been directly     
           affected by the unmet need for such a class of medications.      
                                                                            
BOOKINGS:  We can arrange for an interview with King Robson, who has been   
           interviewed by leading health care newsmakers including NPR, PBS,
           NBC News, Health Radio The Wall Street Journal, More Magazine,   
           The Huffington Post and many others.                             

Contact Information

  • CONTACT:
    Jay Geer
    Miller Geer Arizmendez
    562-467-2020
    Email Contact